Perspectives in Inflammation
Under the Patronage of H.R.H. The Duchess of Kent

Proceedings of an International Meeting on Future Trends in Inflammation III

Organized by The European Biological Research Association

Under the auspices of

The Arthritis & Rheumatism Council
The British Pharmacological Society
The British Society of Immunology
The European League Against Rheumatism
The Pathological Society of Great Britain & Ireland
The Royal Society of Medicine

Held at the Grosvenor House Hotel, Park Lane, London, February 14th–18th, 1977
Perspectives in Inflammation

Future Trends and Developments

The Proceedings of the Third International Meeting on Future Trends in Inflammation organized by the European Biological Research Association and held in London, February 14th–18th, 1977

Edited by

D. A. Willoughby
Professor, Department of Experimental Pathology and Rheumatology, St. Bartholomew’s Hospital, London

J. P. Giroud
Professor, Department of Pharmacology, Hôpital Cochin, Paris

G. P. Velo
Professor, Department of Pharmacology, Policlinico Borgo, Rome

MTP
# Contents

<table>
<thead>
<tr>
<th>Preface</th>
<th>xiii</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of Contributors</td>
<td>xv</td>
</tr>
<tr>
<td>SECTION I IMMUNOLOGICAL ASPECTS OF INFLAMMATION</td>
<td>Page</td>
</tr>
<tr>
<td>Chairman: J. L. Turk; Co-Chairman: G. A Voisin</td>
<td></td>
</tr>
<tr>
<td>Co-Chairman's Introductory Remarks—Immunostimulation and immunosuppression of what?</td>
<td>3</td>
</tr>
<tr>
<td>Guy André Voisin</td>
<td></td>
</tr>
<tr>
<td>1. The rationale of using levamisole in the treatment of rheumatoid arthritis</td>
<td>11</td>
</tr>
<tr>
<td>J. Symoens</td>
<td></td>
</tr>
<tr>
<td>2. Immunostimulation, levamisole and rheumatoid arthritis</td>
<td>21</td>
</tr>
<tr>
<td>E. C. Huskisson</td>
<td></td>
</tr>
<tr>
<td>3. The effect of cytotoxic drugs on the formation of mononuclear phagocytes</td>
<td>29</td>
</tr>
<tr>
<td>R. L. Souhami, J. W. B. Bradfield, N. E. Parker</td>
<td></td>
</tr>
<tr>
<td>4. Rheumatoid factor–immunoglobulin G complex precipitation and neutrophil stimulation: an <em>in vitro</em> model for rheumatoid inflammation</td>
<td>39</td>
</tr>
<tr>
<td>R. Turner, H. Mashburn, R. Collins, L. DeChatelet, J. Kaufmann</td>
<td></td>
</tr>
<tr>
<td>Chairman’s Summing-up and Future Trends—Immunological aspects of inflammation—the network of interactions</td>
<td>49</td>
</tr>
<tr>
<td>J. L. Turk</td>
<td></td>
</tr>
<tr>
<td>General Discussion</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>v</td>
</tr>
</tbody>
</table>
Co-Chairman’s Introductory Remarks—Cellular mechanisms in chronic inflammation

P. C. Wilkinson

5. A model for assessing effects of drugs on granulocyte emigration in vivo
   J. F. Borel, Camille Feurer

6. A polymorph abnormality in Crohn’s disease
   G. Loewi, A. Segal, P. Tooth

7. The origin and kinetics of liver macrophages during steady state and inflammation (Abstract)
   R. van Furth, R. W. Crofton

8. Lymphocyte-mediated eosinophilia in guinea pigs with delayed hypersensitivity to a chemical
   W. E. Parrish, E. Luckhurst

9. A role for L-lymphocytes in chronic inflammation
   David A. Horwitz

10. Cartilage degradation by macrophages, fibroblasts and synovial cells in culture. An in vitro model suitable for studies on rheumatoid arthritis
    G. Vaes, P. Hauser, G. Huybrechts-Godin, C. Peeters-Joris

11. Adjuvant arthritis: immune responses and effects of Tilorone or interferon in partially suppressing the disease
    Carl M. Pearson, Yi-Han Chang

General Discussion

Chairman’s Summing-up and Future Trends—Cellular reactions in inflammation

A. C. Allison

SECTION III CHRONIC INFLAMMATION: MECHANISMS

Chairman: L. E. Glynn; Co-Chairman: I. Ginsburg

Co-Chairman’s Introductory Remarks—The role played by leukocyte extracts and inflammatory exudates in the release of lipopolysaccharides from Gram negative bacteria: relation to tissue damage induced during infections

I. Ginsberg, Z. Duchan, S. Bergner-Rabinowitz, M. Ferne
CONTENTS

12. The effect of local elevation of leukocyte cyclic AMP content on lysosomal enzyme release during acute inflammation in vivo
   D. A. Deporter
   169

13. Recent studies on the secretory activity of mononuclear phagocytes with special reference to prostaglandins
   P. Davies, R. J. Bonney, M. E. Dahlgren, L. Pelus, F. A. Kuehl, Jr., J. L. Humes
   179

14. Interactions of macrophages and complement components in the pathogenesis of chronic inflammation
   H. U. Schorlemmer, J. Ferluga, A. C. Allison
   191

15. Matrix vesicles and apatite nodules in arthritic cartilage
   S. Yousuf Ali
   211

16. Crystal induced inflammation and osteoarthritis
   P. A. Dieppe
   225

17. Microanalysis of particulate material involved in inflammation
   P. A. Dieppe, P. R. Crocker, D. A. Willoughby
   233

18. The influence of chemical composition of plasma membranes on the functional activities of macrophages
   M. Dianzani, F. Feo, R. A. Canuto, R. Garcea, L. Gabriel, M. V. Torrielli
   239

Opening to Discussion—Mechanisms in chronic inflammation
   A. Cats
   251

General Discussion
   255

Chairman’s Summing-up and Future Trends
   L. E. Glynn
   259

SECTION IV GENERAL ASPECTS 1

Chairman: J. P. Giroud, Co-Chairman: K. Brune

19. Dual function of E-type prostaglandins in models of chronic inflammation
   I. L. Bonta, M. J. Parnham, M. J. P. Adolfs, L. van Vliet
   265

20. Interactions between prostaglandin E and cyclic nucleotides in chronic inflammatory disease
   M. J. Parnham, I. L. Bonta, M. J. P. Adolfs
   279

21. The time course of the vascular events associated with inflammation due to ultraviolet irradiation of guinea pig ears
   D. F. Woodward, D. A. A. Owen
   289
22. Role of macrophages in D-penicillamine-induced stimulation of DNA synthesis in lymph node cells in vitro
   E. Arrigoni-Martelli, L. Binderup, E. Bramm

23. Anti-inflammatory effects of tumour bearing
   S. Norman, E. Sorkin

24. Role of platelets and of prostaglandin synthetase on hypotensive effects of arachidonic acid and of carrageenan
   Bernardo B. Vargaftig, Jean Lefort

25. Evidence for a pivotal role of the endoperoxide, PGG2, in inflammatory processes
   F. A. Kuehl, Jr., J. L. Humes, R. W. Egan

26. Thiols and prostaglandin biosynthesis
   C. Deby, Z. M. Bacq, P. van Caneghem

27. Interactions of non-steroidal anti-inflammatory drugs with substance P-like and gastrointestinal hormones-like polypeptides
   J. P. Famaey, J. Fontaine, J. Reuse

28. Salicylic acid and proquazone: the differences in absorption and biodistribution explain their different profile of side-effects
   Alain Schweitzer, Kay Brune

29. Degradation of bovine nasal cartilage by a neutral protease from human leukocyte granules
   D. Kruze, P. Salgam, K. Fehr, A. Boni

30. Inhibition of experimental ocular inflammation by topical application of non-steroidal anti-inflammatory drugs (NSAID)
   P. Gautheron, Ph. Conquet, J. C. LeDouarec

31. Potentiation of acenocoumarin-induced anticoagulation by a new anti-inflammatory agent in man (Abstract)

   A. Tursi, M. P. Loria, G. Specchia, L. Bonomo

SECTION V GENERAL ASPECTS II
Chairman: G. P. Velo; Co-Chairman: J. Sondergaard

33. Potentiation of antibody formation by proteases in vitro
   Thomas L. Vischer
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Triggers of prostaglandin release from macrophages</td>
<td>Marcus Glatt, Kathy Wagner, Kay Brune</td>
</tr>
<tr>
<td>35</td>
<td>Biological, chemical and pharmacological induction of the properdin-mediated pathway of complement activation in vitro</td>
<td>T. Di Perri, A. Auteri, F. Laghi Pasini, F. Mattioli</td>
</tr>
<tr>
<td>36</td>
<td>Immune reactions of lymphocytes eluted from rheumatoid inflammatory tissue</td>
<td>T. G. Abrahamsen, S. S. Fröhland, J. B. Natvig, J. Pahle</td>
</tr>
<tr>
<td>37</td>
<td>Attempts at producing immune complexes in vitro between isolated macroglobulins and purified IgGs</td>
<td>Nanna Svartz</td>
</tr>
<tr>
<td>38</td>
<td>Behaviour of some inflammation parameters in plasma and synovial fluid in some rheumatic diseases (Abstract)</td>
<td>R. Numo, V. Pipitone</td>
</tr>
<tr>
<td>39</td>
<td>Some applications of quantitative two-dimensional immunoelectrophoresis in the study of the systemic acute-phase reaction of the rat</td>
<td>R. Scherer, M. Abd-el-Fattah, G. Ruhenstroth-Bauer</td>
</tr>
<tr>
<td>40</td>
<td>Restoration of the neutrophil chemotactic responsiveness by levamisole treatment in patients with recurrent infections, eczema and hyperimmunoglobulinaemia E</td>
<td>R. S. Weening, Liesbeth Stricker, D. Roos, J. L. Molenaar, L. J. Dooren, R. K. B. Schuurman</td>
</tr>
<tr>
<td>41</td>
<td>Rheumatoid-like joint lesions in rabbits injected intravenously with foreign serum</td>
<td>A. R. Poole, R. R. A. Coombs</td>
</tr>
<tr>
<td>42</td>
<td>Anti-inflammatory activity of some bacterial immunostimulants. Relation with macrophage migration</td>
<td>P. Lallouette, A. Schwartz</td>
</tr>
<tr>
<td>43</td>
<td>Inflammatory exudates and mitogenic activity</td>
<td>M. Adolphe, J. Fontagne, M. Pelletier, D. Blondelon, P. Lechat, J. P. Giroud</td>
</tr>
<tr>
<td>44</td>
<td>Secretory activity of epithelioid cells</td>
<td>N. Mokhtar, W. G. Spector</td>
</tr>
<tr>
<td>45</td>
<td>Vascular changes during acute inflammatory responses in rat hindpaws</td>
<td>D. A. A. Owen</td>
</tr>
</tbody>
</table>
PERSPECTIVES IN INFLAMMATION

SECTION VI  PHARMACOLOGICAL ASPECTS: ANIMAL/MAN

Chairman: C. M. Pearson

46. Activators and inhibitors of fibrinolysis in rheumatoid joint inflammation
   L. B. A. van de Putte, C. Kluft, V. Noordhoek Hegt, G. Wijngaards, F. Haverkate, A. Cats

47. Relationships between increased vascular permeability, oedema, hyperalgesia and the effect of non-steroid anti-inflammatory drugs
   S. H. Ferreira, Maria Teresinha Zanin, Berenice B. Lorenzetti

48. Two sites of action of steroids on the prostaglandin system
   G. P. Lewis, P. J. Piper

49. Studies on the clinical and laboratory pharmacology of drug formulations of bovine Cu–Zn superoxide dismutases (orgotein)
   W. Huber, K. B. Menander-Huber, M. G. P. Saifer, P. H-C. Dang

50. Humoral control of monocytopoiesis (Abstract)
   D. van Waarde, E. Hulsing-Hesselink

General Discussion

Chairman’s Summing-up and Future Trends
C. M. Pearson

SECTION VII  PHARMACOLOGICAL ASPECTS: MAN/ANIMAL

Chairman: D. A. Willoughby; Co-Chairman: P. Franchimont

Co-Chairman’s Opening Remarks
   P. Franchimont, G. Heynen

51. Difficulties in the clinical evaluation of new anti-inflammatory drugs
   G. Katona

52. Is the mechanism of action during treatment of rheumatoid arthritis with penicillamine and gold thiomalate the same?
   Egil Jellum, Eimar Munthe

53. About immunological anomalies in treated and non-treated rheumatoid arthritis: rosette test and immunofluorescence of B-cells
   H. Roux, P. Mercier, Y. Jeandel, M. T. Gabriel-Brouillet, G. Serratrice
CONTENTS

54. Should penicillamine be prescribed for rheumatoid arthritis? 591
    W. H. Lyle

55. Long-term evaluation of intermittent levamisole treatment in
    rheumatoid arthritis
    E. M. Veys, H. Mielants

General Discussion 610

Closing Remarks 616
    D. A. Willoughby

POSTER SESSIONS 619
Preface

This report on Future Trends in Inflammation III is the record of what is now firmly established as a series of multidisciplinary meetings organized by the European Biological Research Association. The aim of these meetings is to provide a forum for free exchange of information between basic scientists of many disciplines and clinicians to provide better understanding of problems of common interest. The next major meeting will be held in 1980.*

The European Biological Research Association promotes scientific and clinical collaboration among the member countries of the EEC. It encourages exchange of information between scientists and clinicians from centres all over the world. In addition to the major international meetings small workshops are organized on specific problems of common interest.

Once again the Editors have attempted to capture the spirit of the meeting by publishing 'verbatim' the discussion. It can be seen that the discussions were exciting and formed an important part of the meeting.

It is possible that inaccuracies have crept into the discussions; if so we apologize. It was decided that the proceedings of such a meeting had maximum value with rapid publication.

We would like to thank the participants for the enthusiasm and goodwill which persisted throughout the meeting both scientifically and socially.

Above all we wish to thank H.R.H. The Duchess of Kent for acting as Patron of this meeting.

D. A. Willoughby
J. P. Giroud
G. P. Velo

* For further information regarding the 1980 meeting please contact Professor D. A. Willoughby of Department of Experimental Pathology, St. Bartholomew's Hospital, London, EC1A 7BE, England.
List of Contributors

JAN AASETH
Institute of Clinical Biochemistry,
Rikshospitalet, Oslo, 1, Norway

M. ABD-EL-FATTAH
Department of Biochemistry, Faculty of
Science, Ain Sams University, Cairo,
Egypt

T. G. ABRAHAMSEN
Institute of Immunology and
Rheumatology, Rikshospitalet, Oslo 1,
Norway

M. J. P. ADOLFS
Department of Pharmacology, Faculty of
Medicine, Erasmus University,
Rotterdam, The Netherlands

M. ADOLPHE
Laboratory of Cellular Pharmacology,
College for Advanced Studies,
Centre de Recherches de l’Association
Claude Bernard, F-75006 Paris, France

S. YOUSUF ALI
Experimental Pathology Unit, Institute of
Orthopaedics, University of London,
Royal National Orthopaedic Hospital,
Stanmore, Middlesex, HA7 4LP

A. C. ALLISON
MRC Clinical Research Centre,
Harrow, Middlesex, HA1 3UJ

E. ARRIGONI-MARTELLI
Department of Pharmacology,
Leo Pharmaceutical Products,
DK-2750 Ballerup, Denmark

A. AUTERI
Institute of Medical Semiotics, School of
Medicine, University of Sienna, Italy

Z. M. BACQ
Applied Biochemistry Laboratory,
University of Liege, B-4020 Liege,
Belgium

S. BERGNER-RABINOWITZ
The Department of Oral Biology,
Hadassah School of Medicine,
The Hebrew University, Jerusalem,
Israel

G. BIANCHETTI
Rheumatology Service, L. Sacco Hospital,
Milan, Italy

L. BINDERP
Department of Pharmacology,
Leo Pharmaceutical Products,
DK-2750 Ballerup, Denmark

D. BLANDELON
Laboratory of Cellular Pharmacology,
College for Advanced Studies, Centre de
Recherches de l’Association Claude
Bernard, F-75006 Paris, France

A. BÖNI
Department of Rheumatology, University
of Zurich, Cantonal Hospital, CH-8091
Zurich, Switzerland

R. J. BONNEY
Merck Institute for Therapeutic Research,
Rahway, New Jersey 07065, USA

L. BONOMO
Institute of Clinical Medicine II,
University of Bari, Policlinico, I-70124,
Bari, Italy

I. L. BONTA
Department of Pharmacology, Faculty
of Medicine, Erasmus University,
Rotterdam, The Netherlands

J. F. BOREL
Biological and Medical Research
PERSPECTIVES IN INFLAMMATION

Division, Sandoz Ltd., CH-4002 Basel, Switzerland

J. W. D. BRADFIELDDepartment of Experimental Pathology, St. Mary’s Hospital Medical School, London, W.2

E. BRAMMDepartment of Pathology, Leo Pharmaceutical Products, DK-2750 Ballerup, Denmark

K. BRUNEUniversity of Basel, CH-4056 Basel, Switzerland

P. van CANEGHEMAPplied Biochemistry Laboratory, University of Liege, B-4020 Liege, Belgium

R. A. CANUTOInstitute of General Pathology, University of Turin, I-10125 Turin, Italy

L. CARRATELLIMERck Sharp and Dohme (Italia) S.p.a., I-00191 Rome, Italy

L. CARUSORheumatology Service, L. Sacco Hospital, Milan, Italy

A. CATSDepartment of Rheumatology, University Hospital, Leiden, The Netherlands

Y.-H. CHANGDivision of Rheumatology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA

L. DeCHATELETDepartment of Biochemistry, The Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103, USA

R. COLLINSDepartment of Biochemistry, The Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103, USA

Ph. CONQUETMSD-Chibret Research Institute, F-63018 Clermont-Ferrand, France

R. R. A. COOMBSDivision of Immunology, Department of Pathology, University of Cambridge

P. R. CROCKERDepartment of Rheumatology and Experimental Pathology, St. Bartholomew’s Hospital, London, E.C.1

R. W. CROFTONDepartment of Infectious Diseases, University Hospital, Leiden, The Netherlands

M. E. DAHLGRENMerck Institute for Therapeutic Research, Rahway, New Jersey 07065, USA

P. H.-C. DANGDiagnostic Data Inc., Mountain View, California 94043, USA

P. DAVIESMerck Institute for Therapeutic Research, Rahway, New Jersey 07065, USA

C. DEBYApplied Biochemistry Laboratory, University of Liege, B-4020 Liege, Belgium

D. A. DEPORTERFaculty of Dentistry, University of Toronto, Toronto, Canada

M. DIANZANIInstitute of General Pathology, University of Turin, I-10125 Turin, Italy

P. A. DIEPPEDepartment of Rheumatology and Experimental Pathology, St. Bartholomew’s Hospital, London, E.C.1

M. B. DONATIRheumatology Service, L. Sacco Hospital, Milan, Italy

L. J. DOORENDepartment of Paediatrics, University Hospital, Leiden, The Netherlands

J. C. LéDOUARECMSD-Chibret Research Institute, F-63018 Clermont-Ferrand, France
LIST OF CONTRIBUTORS

Z. DUCHAN
The Department of Oral Biology,
Hadassah School of Medicine, The
Hebrew University, Jerusalem, Israel

R. W. EGAN
Merck Institute for Therapeutic
Research, Rahway, New Jersey 07065,
USA

J. P. FAMAELY
Laboratory of Pharmacology,
Rheumatology Unit, School of Medicine,
University of Brussels, B-1000 Brussels,
Belgium

K. FEHR
Department of Rheumatology, University
of Zurich, Cantonal Hospital, CH-8091
Zurich, Switzerland

F. FEO
Institute of General Pathology,
University of Turin, I-10125 Turin,
Italy

J. FERLUGA
Institute of Medical Microbiology,
Johannes Gutenberg University, D-6500
Mainz, West Germany

M. FERNE
The Department of Oral Biology,
Hadassah Medical School, The Hebrew
University, Jerusalem, Israel

S. H. FERREIRA
Department of Pharmacology, Faculty
of Medicine, University of Sao Paulo,
Sao Paulo, Brazil

CAMILLE FEURER
Biological and Medical Research Division,
Sandoz Ltd., CH-4002 Basel,
Switzerland

J. FONTAGNE
Laboratory of Cellular Pharmacology,
College for Advanced Studies, Centre de
Recherches de l'Association Claude
Bernard, F-75006 Paris, France

J. FONTAINE
Laboratory of Pharmacology,
Rheumatology Unit, School of Medicine,
University of Brussels, B-1000 Brussels,
Belgium

P. FRANCHIMONT
Radioimmunochemistry Laboratory, University
of Liege, B-4000 Liege, Belgium

S. S. FRÖHLAND
Institute of Immunology and
Rheumatology, Rikshospitalet, Oslo 1,
Norway

M. FUMGALLI
Rheumatology Service, L. Sacco Hospital,
Milan, Italy

R. van FURTH
Department of Infectious Diseases,
University Hospital, Leiden, The
Netherlands

L. GABRIEL
Institute of General Pathology,
University of Turin, I-10125 Turin,
Italy

M. T. GABRIEL-BROUILLET
Rheumatology Clinic, C.H.U. Tirrone,
Marseilles, France

R. GARCEA
Institute of General Pathology, University
of Turin, I-10125 Turin, Italy

P. GAUTHERON
MSD-Chibret Research Institute, F-63018
Clermont-Ferrand, France

I. GINSBURG
The Department of Oral Biology,
Hadassah School of Medicine, The
Hebrew University, Jerusalem, Israel

J. P. GIROUD
Department of Pharmacology, Hospital
Cochin, Paris 14, France

M. GLATT
Department of Pharmacology, University
of Basel, CH-4056 Basel, Switzerland

L. E. GLYNN
Kennedy Institute of Rheumatology,
Hammersmith, London W6 7DW

P. HAUSER
Laboratory of Physiological Chemistry,
University of Leuven, Leuven, Belgium
F. HAVERKATE
Gaubius Institute, Health Research Organization TNO, Leiden, The Netherlands

G. HEYREN
Radioimmunology Laboratory, University of Liege, B-4000 Liege, Belgium

D. A. HOROWITZ
Division of Rheumatology, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22901, USA

W. HUBER
Diagnostic Data Inc., Mountain View, California 94043, USA

E. HULSING-HESSELINK
Department of Infectious Diseases, University Hospital, Leiden, The Netherlands

J. L. HUMES
Merck Institute for Therapeutic Research, Rahway, New Jersey 07065, USA

E. C. HUSKISSON
St. Bartholomew's Hospital, London

G. HUYBRECHT-GODIN
Laboratory of Physiological Chemistry, University of Leuven, Leuven, Belgium

Y. JEANDEL
Rheumatology Clinic, C.H.U. Tirrone, Marseilles, France

E. JELLUM
Institute of Clinical Biochemistry, Rikshospitalet, Oslo 1, Norway

G. KATONA
Rheumatology Service, General Hospital, Mexico City, Mexico, D. F.

J. KAUFMANN
Department of Biochemistry, The Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103, USA

C. KLUIT
Department of Rheumatology, University Hospital, Leiden, The Netherlands

D. KRUZE
Department of Rheumatology, University of Zurich, Cantonal Hospital, CH-8091 Zurich, Switzerland

F. A. KUEHL, Jr.
Merck Institute for Therapeutic Research, Rahway, New Jersey 07065, USA

P. LALLOUETTE
41, rue Camille Pelletan, F-92305 Levallois-Perret, France

R. LATINI
Rheumatology Service, L. Sacco Hospital, Milan, Italy

P. LECHAT
Laboratory of Cellular Pharmacology, College for Advanced Studies, Centre de Recherches de l'Association Claude Bernard, F-75006 Paris, France

J. LEFORT
Centre de Recherches Merrell International F-67084 Strasbourg, France

G. P. LEWIS
Department of Pharmacology, Royal College of Surgeons of England, London, WC2A 3PN

G. LOEWI
MRC Clinical Research Centre, Harrow, Middlesex, HA1 3UJ

BERENICE B. LORENZETTI
Department of Pharmacology, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

M. P. LORIA
Institute of Clinical Medicine II, University of Bari, Policlinico, I-70124, Bari, Italy

E. LUCKHURST
Lister Institute of Preventive Medicine, Elstree, Herts

W. H. LYLE
Dista Products Limited, Speke, Liverpool, L24 9LN

H. MASHBURN
Department of Biochemistry, The Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103, USA
LIST OF CONTRIBUTORS

K. B. MENANDER-HUBER
Diagnostic Data Inc., Mountain View, California 94043, USA

W. E. PARISH
Unilever Research, Colworth House, Sharnbrook, Bedford

P. MERCIER
Transfusion Centre, Marseilles, France

N. E. PARKER
University College Hospital Medical School, London

H. MIELANTS
Section of Rheumatology, University Hospital, B-9000 Ghent, Belgium

M. J. PARNHAM
Department of Pharmacology, Faculty of Medicine, Erasmus University, Rotterdam, The Netherlands

N. MOKHTAR
Department of Pathology, St. Bartholomew’s Hospital Medical College, London

F. LAGHI PASINI
Institute of Medical Semiotics, School of Medicine, University of Sienna, Sienna, Italy

J. L. MOLENAAR
Central Laboratory of the Netherlands’ Red Cross Blood Transfusion Service, Amsterdam, The Netherlands

C. M. PEARSON
Division of Rheumatology, Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA

F. MONTRONE
Rheumatology Service, L. Sacco Hospital, Milan, Italy

C. PEETERS-JORIS
Laboratory of Physiological Chemistry, University of Leuven, Leuven, Belgium

E. MUNTHE
Oslo Rheumatism Hospital, Oslo 1, Norway

M. PELLETIER
Laboratory of Cellular Pharmacology, College for Advanced Studies, Centre de Recherches de l’Association Claude Bernard, F-75006 Paris, France

J. B. NATVIG
Oslo Rheumatism Hospital, Oslo 1, Norway

L. PELUS
Merck Institute for Therapeutic Research, Rahway, New Jersey 07065, USA

V. NOORDHOEK HEGT
Gabius Institute, Health Research Organization TNO, Leiden, The Netherlands

T. DI PERRI
Institute of Medical Semiotics, School of Medicine, University of Sienna, Sienna, Italy

S. NORMANN
Department of Pathology, College of Medicine, University of Florida, Gainesville, Florida 32610, USA

P. J. PIPER
Department of Pharmacology, Royal College of Surgeons of England, London, WC2A 3PN

R. NUMO
Rheumatology Service, University of Bari, Policlinico, I-70124 Bari, Italy

V. PIPITONE
Rheumatology Service, University of Bari, Policlinico, I-70124 Bari, Italy

D. A. A. OWEN
Department of Pharmacology, The Research Institute, Smith Kline and French Laboratories Ltd., Welwyn Garden City, Herts

A. R. POOLE
Joint Diseases Laboratory, Shriners Hospital for Crippled Children, Montreal, Quebec, H3G 1A6, Canada

J. PAHLE
Oslo Rheumatism Hospital, Oslo 1, Norway

L. B. A. van de PUTTE
Department of Rheumatology, University Hospital, Leiden, The Netherlands

xix
PERSPECTIVES IN INFLAMMATION

J. REUSSE
Laboratory of Pharmacology,
Rheumatology Unit, School of Medicine,
University of Brussels, B-1000 Brussels,
Belgium

D. ROOS
Central Laboratory of the Netherlands’
Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands

H. ROUX
Rheumatology Clinic, C.H.U. Tirrone,
Marseilles, France

G. RUHENSTROTH-BAUER
Max-Planck-Institute for Biochemistry,
D-8032 Martinsried bei München, West
Germany

M. G. P. SAIFER
Diagnostic Data Inc., Mountain View,
California 94043, USA

A. SEGAL
MRC Clinical Research Centre, Harrow,
Middlesex, HA1 3UJ

R. SCHERER
Max-Planck-Institute for Biochemistry,
D-8032 Martinsried bei München, West
Germany

H. U. SCHORLEMMER
Institute for Medical Microbiology,
Johannes Gutenberg University, D-6500
Mainz, West Germany

R. K. B. SCHUURMAN
Sophia Children’s Hospital, Rotterdam,
The Netherlands

A. SCHWARTZ
41, rue Camille Pelleton, F-92305
Levallois-Perret, France

A. SCHWEITZER
Department of Biopharmaceutics,
Sandoz AG, CH-4002 Basel,
Switzerland

A. SEGAL
MRC Clinical Research Centre, Harrow
Middlesex, HA1 3UJ

G. SERRATRICE
Rheumatology Clinic, C.H.U. Tirrone,
Marseilles, France

J. SONDERGAARD
Department of Dermatology, Hvidovre
Hospital, Hvidovre, Denmark

E. SORKIN
Department of Medicine, Swiss Research
Institute, CH-7270 Davos, Switzerland

R. L. SOUHAMI
University College Hospital Medical
School, London

G. SPECCHIA
Institute of Clinical Medicine II,
University of Bari Medical School,
I-70124 Bari, Italy

W. G. SPECTOR
Department of Pathology, St.
Bartholomew’s Medical College, London

LIESBETH STRICKER
Central Laboratory of the Netherlands’
Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands

NANNA SVARTZ
King Gustav V Research Institute, S-10
401 Stockholm, Sweden

J. SYMOENS
Department of Clinical Research,
Janssen Pharmaceutica Research
Laboratories, B-2340 Beerse, Belgium

P. TOOTH
MRC Clinical Research Centre, Harrow,
Middlesex, HA1 3UJ

M. V. TORRIELLI
Institute of General Pathology,
University of Turin, I-10125 Turin, Italy

J. L. TURK
Department of Pathology, Royal College
of Surgeons of England, London,
WC2A 3PN

R. TURNER
Department of Medicine, The Bowman
Gray School of Medicine, Wake Forest
University, Winston-Salem, North
Carolina 27103, USA

A. TURSI
Institute of Clinical Medicine II,
University of Bari Medical School,
I-70124 Bari, Italy
LIST OF CONTRIBUTORS

B. VARGAFTIG
Centre de Recherche Merrell International,
F-67084 Strasbourg, France

G. VAES
Laboratory of Physiological Chemistry,
University of Leuven, Leuven, Belgium

G. P. VELO
Department of Pharmacology,
Policlinico Borgo Roma, I-37100 Verona,
Italy

E. M. VEYS
Rheumatology Section, University
Hospital, B-9000 Ghent, Belgium

T. L. VISCHER
Department of Rheumatology,
University of Geneva, Hôpital Cantonal
CH-1211 Geneva, Switzerland

L. van VLIET
Department of Pharmacology, Faculty
of Medicine, Erasmus University,
Rotterdam, The Netherlands

G. A. VOISIN
Centre of Immuno-Pathology and
Experimental Immunology,
l’Association Claude Bernard, Hôpital
Saint-Antoine, F-75012 Paris, France

D. van WAARDE
Department of Infectious Diseases,
University Hospital, Leiden, The
Netherlands

KÄTHY WAGNER
Department of Pharmacology, University
of Basel, CH-4056 Basel, Switzerland

R. S. WEENING
Central Laboratory of the Netherlands’
Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands

G. WIJNGAARDS
Gaubius Institute, Health Research
Organization TNO, Leiden, The
Netherlands

P. C. WILKINSON
Bacteriology and Immunology
Department, University of Glasgow,
Western Infirmary, Glasgow, G11 6NT

D. A. WILLOUGHBY
Department of Rheumatology and
Experimental Pathology, St.
Bartholomew’s Hospital, London,
E.C.1

D. F. WOODWARD
Department of Pathology, The Research
Institute, Smith Kline and French
Laboratories Limited, Welwyn Garden
City, Herts

MARIA TERESINHA ZANIN
Department of Pharmacology, Faculty
of Medicine, University of Sao Paulo,
Sao Paulo, Brazil